ScholarIQanswers from OpenAlex & ORCID
Lars Bullinger
ResearcherPublications, citations & collaboration network
Lars Bullinger is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Lars Bullinger have?
ScholarIQindexed works
Lars Bullinger has 960 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Lars Bullinger have?
ScholarIQcitation count
Lars Bullinger has 43,801 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Lars Bullinger?
ScholarIQh-index
Lars Bullinger has an h-index of 96 in OpenAlex.
What is the i10-index of Lars Bullinger?
ScholarIQi10-index
Lars Bullinger has an i10-index of 325 in OpenAlex.
What is the ORCID of Lars Bullinger?
ScholarIQorcid
The ORCID for Lars Bullinger is on the source record.
What is the OpenAlex record for Lars Bullinger?
ScholarIQopenalex
The OpenAlex for Lars Bullinger is on the source record.
What are the most-cited papers on Lars Bullinger?
ScholarIQmost cited works
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Kathrin M. Bernt, Nan Zhu, Amit Sinha, Sridhar Vempati, Joerg Faber, Andrei V. Krivtsov, Zhaohui Feng, Natalie Punt, Amanda J. Daigle, Lars Bullinger, Roy M. Pollock, Victoria M. Richon, Andrew L. Kung, Scott A. Armstrong
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, Joachim P. Steinbach, Uwe Schlegel, Michael Sabel, Peter Hau, Rolf‐Dieter Kortmann, Dietmar Krex, Oliver Grauer, Roland Goldbrunner, Oliver Schnell, Oliver Bähr, Martin Uhl, Clemens Seidel, Ghazaleh Tabatabai, Thomas E. Kowalski, Florian Ringel, Friederike Schmidt‐Graf, Bogdana Suchorska, Stefanie Brehmer, Astrid Weyerbrock, Miriam Renovanz, Lars Bullinger, Norbert Galldiks, Peter Vajkoczy, Martin Misch, Hartmut Vatter, Moritz Stuplich, Niklas Schäfer, Sied Kebir, Johannes Weller, Christina Schaub, Walter Stummer, Jörg‐Christian Tonn, Matthias Simon, Vera C. Keil, Michael Nelles, Horst Urbach, Martin Coenen, Wolfgang Wick, Michael Weller, Rolf Fimmers, Matthias Schmid, Elke Hattingen, Torsten Pietsch, Christoph Coch, Martin Glas
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael Wenger, Günter Fingerle‐Rowson, Peter Lichter, Mario Cazzola, Clemens‐Martin Wendtner, Anna Maria Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, Hartmut Döhner
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia
Michael G. Kharas, Christopher J. Lengner, Fátima Al‐Shahrour, Lars Bullinger, Brian Ball, Samir Zaidi, Kelly Morgan, Winnie F. Tam, Mahnaz Paktinat, Rachel Okabe, Maricel Gozo, William S. Einhorn, Steven Lane, Claudia Scholl, Stefan Fröhling, Mark D. Fleming, Benjamin L. Ebert, D. Gary Gilliland, Rudolf Jaenisch, George Q. Daley
AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias
Stephen M. Sykes, Steven Lane, Lars Bullinger, Demetrios Kalaitzidis, Rushdia Z. Yusuf, Borja Sáez, Francesca Ferraro, François Mercier, Harshabad Singh, Kristina Brumme, Sanket S. Acharya, Claudia Scholl, Zuzana Tóthová, Eyal C. Attar, Stefan Fröhling, Ronald A. DePinho, D. Gary Gilliland, Scott A. Armstrong, David T. Scadden